More than 600,000 prescriptions have been issued for oral semaglutide weight loss drug; Novo Nordisk CEO says weight loss drug market has only scratched the surface
Golden Ten Data April 6｜According to the latest disclosed data from Novo Nordisk, prescriptions for its oral weight loss drug semaglutide currently exceed 600,000. UBS estimates that the combined revenue of Eli Lilly’s oral weight loss drug and Novo Nordisk’s oral version of semaglutide will reach approximately 5 billion USD in 2026. However, in the view of Novo Nordisk’s CEO, the weight loss drug market is vast, and the pharmaceutical industry has only scratched the surface. He stated that, including Novo Nordisk, Eli Lilly, and several U.S. producers of compound weight loss drugs, the current supply of weight loss medications can meet only 10% to 15% of the demand among obesity patients.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barclays: Bloom Energy (BE.US) demand turning point is steeper than expected, rating raised to "Buy"
Barclays has upgraded Bloom Energy’s rating from "equal weight" to "overweight," setting a target price of $289.
Competitor turns supplier as the "new owner"! Bank of America: Marvell Technology's acquisition of Lumentum may prompt Cisco and Ciena to seek other sources
Bank of America analysts stated that Marvell Technology's acquisition of Lumentum may prompt Ciena and Cisco to diversify their optical component suppliers.
Goldman Sachs traders warn of an "invisible bear market": S&P 500 is only 3% away from its all-time high, but 60% of its constituent stocks have entered bear market territory.
The S&P 500 Index is only about 3% away from its latest record high, but 60% of the constituent stocks in this benchmark index are deeply entrenched in bear market territory.
Crypto prices
More
